Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (641)	1/9/2003 3:38:21 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

GENMAB ACHIEVES FIRST MILESTONE IN ROCHE ANTIBODY COLLABORATION Copenhagen, Denmark; January 9, 2003 – Genmab A/S (CSE: GEN) announced today that it has achieved the first milestone in its collaboration with Roche, as a human antibody generated by Genmab has effectively reached proof of concept in an animal disease model. “This milestone is an important step forward for our collaboration with Roche,” said Lisa N. Drakeman, Ph. D., Chief Executive Officer of Genmab. “We are working effectively with Roche to develop promising new product candidates.” In this collaboration Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Roche’s efforts are based on the company’s commitment to the development of biologicals as innovative new products. Under the current agreement, Genmab will receive milestones as well as royalty payments on successful products. In certain circumstances Genmab could obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration to Genmab could be as high as US$100 Million plus royalties.